-
公开(公告)号：US20220280721A1
公开(公告)日：2022-09-08
申请号：US17684652
申请日：2022-03-02
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments provide more customized basal insulin amounts for users to better regulate blood glucose (BG) concentration levels. The exemplary embodiments do not statically assume that the daily basal amount for each user is 50% of TDI. Instead, actual TDI data may be gathered for each user and may be used to adjust the TDI value for that user to an updated value. In addition, the ratio of basal to TDI may be adjusted for the user based on the actual ratio determined from data gathered over one or more days. As a result, better BG concentration level control may be realized.
-
公开(公告)号：US20210249115A1
公开(公告)日：2021-08-12
申请号：US16787223
申请日：2020-02-11
Applicant: INSULET CORPORATION
Inventor： David NAZZARO , Steven CARDINALI , Nicholas CONTE , Daniel ALLIS , Jason O'CONNOR , Joon Bok LEE , Ashutosh ZADE , Timothy HENNING , Thomas METZMAKER , Ian MCLAUGHLIN
Abstract: Disclosed are examples of a device, a system, methods and computer-readable medium products operable to implement functionality to determine and respond to a purpose of a meal. An algorithm or application may receive data that may include data related to a meal purpose from data sources and determine whether any of the data received from the plurality of data sources was received from a direct data source or an indirect data source. The data may be evaluated to determine a purpose of the meal. Based on the results of the evaluation, instructions may be generated to provide an appropriate response based on the determined purpose of the meal. The generated instructions to provide the appropriate response based on the determined purpose of the meal may be output.
-
公开(公告)号：US20210244881A1
公开(公告)日：2021-08-12
申请号：US16789051
申请日：2020-02-12
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.
-
公开(公告)号：US20210137427A1
公开(公告)日：2021-05-13
申请号：US17096565
申请日：2020-11-12
Applicant: INSULET CORPORATION
Inventor： Steven CARDINALI , Joon Bok LEE
Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques for evaluating and modifying a duration of insulin action setting usable by an automatic medication delivery algorithm, such as an artificial pancreas application.
-
公开(公告)号：US20190336684A1
公开(公告)日：2019-11-07
申请号：US16404456
申请日：2019-05-06
Applicant: Insulet Corporation
Inventor： Jason O'CONNOR , Joon Bok LEE , Trang LY , Yibin ZHENG , Thomas Arnold PEYSER , Jennifer Lena SCHNEIDER
Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
-
Patent Agency Ranking
公开(公告)号：US20240374813A1
公开(公告)日：2024-11-14
申请号：US18661020
申请日：2024-05-10
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Gregory STERN , Nika VARPAHOVSKY , Jason O’CONNOR
Abstract: Exemplary embodiments calculate a user's progress towards maximum adapted system performance when utilizing a drug delivery device such as an insulin pump and display this progress to the user. Further embodiments calculate potential changes to a particular user's interaction with the system given a history of glucose and insulin deliveries and provide guidance to that user. This can be used, for example, to change how the user splits up their basal and bolus doses to improve metrics such as time-in-range, incidences of hyper- or hypo-glycemia, time in hyper- or hypo-glycemia, mean glucose, etc. It may also be used to speed the above-described adaptation process by suggesting changes that the user can make to achieve stability more quickly.
-
公开(公告)号：US20240293617A1
公开(公告)日：2024-09-05
申请号：US18436410
申请日：2024-02-08
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Mengdi LI , Jason O'CONNOR , Yibin ZHENG
IPC: A61M5/172 , G16H10/40 , G16H10/60 , G16H20/17 , G16H40/60 , G16H40/67 , G16H50/20 , G16H50/30 , G16H50/50 , G16H50/70 , H04L67/141
CPC classification number: A61M5/1723 , G16H10/40 , G16H10/60 , G16H20/17 , G16H40/60 , G16H40/67 , G16H50/20 , G16H50/30 , G16H50/50 , G16H50/70 , A61M2202/07 , A61M2205/3584 , A61M2205/50 , A61M2205/502 , A61M2230/20 , A61M2230/201 , H04L67/141
Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
-
公开(公告)号：US20240148971A1
公开(公告)日：2024-05-09
申请号：US18386647
申请日：2023-11-03
Applicant: INSULET CORPORATION
Inventor： Matthew ALLES , Yibin ZHENG , Joon Bok LEE , James CAUSEY , Jason O'CONNOR
CPC classification number: A61M5/1723 , A61M5/14248 , A61M2202/0486
Abstract: Exemplary embodiments may provide an on-body medicament delivery system that provides basal delivery of a medicament to a type 2 diabetes patient and that automatically performs medicament titration for the patient. The medicament delivery system performs medicament titration based on glucose level readings for the patient. These glucose levels may be provided wirelessly from a glucose sensor, such as a continuous glucose monitor, or may be entered manually by the patient into a management device, such as a smartphone running an application that provides a user interface for the patient to enter the glucose level readings. The medicament delivery system adjusts the basal medicament delivery rate/dose based on the glucose level readings for the patient. The adjustments may be performed by a programmatic mechanism, such as by computer programming instructions executing on a processor.
-
公开(公告)号：US20240066213A1
公开(公告)日：2024-02-29
申请号：US18453765
申请日：2023-08-22
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Jason O’CONNOR , Yibin ZHENG , Ashutosh ZADE
CPC classification number: A61M5/14248 , A61M5/1723 , A61M2202/0486
Abstract: Disclosed are techniques, devices and systems that modify an insulin delivery schedule based on how sensitive a diabetic user may to fluctuations in their total daily insulin or fluctuations in their blood glucose measurement values. As a control algorithm calculates how to adapt the calculation of the user's total daily insulin, a rate of adaptivity function may be used in the calculation. The rate of adaptivity may depend on a number of factors and the disclosed techniques, devices and systems enable calculation of the rate of adaptivity to provide effective implementation or modification of a diabetic treatment plan.
-
公开(公告)号：US20240000347A1
公开(公告)日：2024-01-04
申请号：US18345371
申请日：2023-06-30
Applicant: INSULET CORPORATION
Inventor： Jason O'CONNOR , Joon Bok LEE , Graeme NELSON
CPC classification number: A61B5/14532 , A61B5/7267 , A61B5/7275 , A61B5/746 , A61B5/743 , A61M2005/1726
Abstract: Disclosed herein is a method, implemented in an automated drug delivery system for determining a risk of a hypoglycemic or hyperglycemic condition based on risk factors calculated each time a new blood glucose reading is received and providing an alert to the user should a risk be determined. The risk factors may include the current CGM reading, the trend of CGM readings, the amount of insulin-on-board of the user and the accuracy of previous alerts provided to the user. The method may be modified to provide the risk of hypoglycemia if the user were to engage in exercise or other physical activities.
-
-
-
-
-
-
-
-
-
Search Results
111
records
(took 0.022 seconds)
